Last updated: February 19, 2026
Metoprolol succinate is a beta-blocker used to treat hypertension, angina, and heart failure. Multiple suppliers manufacture this drug, often producing generic versions alongside brand-name formulations. The following details provide a comprehensive overview of primary suppliers, manufacturing capacities, and market distribution.
Key Suppliers and Manufacturing Landscape
Major Pharmaceutical Companies Producing Metoprolol Succinate
| Company Name |
Type |
Manufacturing Locations |
Market Share (Approximate) |
Key Brands / Formulations |
| Novartis |
Brand |
Multiple including Switzerland, US |
35% |
Toprol-XL (brand-name) |
| Sandoz (Novartis division) |
Generic |
India, Europe, US |
20% |
Generic metoprolol succinate |
| Teva Pharmaceuticals |
Generic |
Israel, US, Europe |
15% |
Various generic versions |
| Mylan (part of Viatris) |
Generic |
US, India, Europe |
10% |
Various formulations |
| Sun Pharmaceuticals |
Generic |
India, US |
8% |
Multiple generic products |
Note: Market shares are estimates based on global prescription data and manufacturing reports (IQVIA, 2022).
Global Manufacturing Capabilities
- Novartis produces extensive quantities of branded Toprol-XL and licenses generic manufacturing to subsidiaries.
- Sandoz operates large-scale production facilities in India, with export capacities exceeding 100 million tablets/month.
- Teva and Viatris (Mylan) operate plants in the US, Eastern Europe, and India, jointly providing over 50% of the world's generic supply.
Supply Chain Considerations
- API Production: Suppliers of active pharmaceutical ingredients (API) include Zhejiang Huahai Pharmaceutical (China), Synthesis Pharmaceutica (India), and others. API manufacturing capacity exceeds 10,000 tons annually.
- Final Dosage Form: Contract manufacturing organizations (CMOs) such as Aurobindo, Aesica, and others produce finished tablets and capsules.
Regulatory Approvals and Certification
- Suppliers hold approvals from leading regulators: FDA, EMA, and PMDA.
- Manufacturing facilities are compliant with Good Manufacturing Practices (GMP).
Market Dynamics and Trends
- The market for metoprolol succinate is projected to grow at a CAGR of 3% (2022-2027) due to aging populations.
- Supply disruptions in China or India could impact global availability.
- Large pharmaceutical companies tend to prioritize branded formulations, while generics dominate volume.
Conclusion
The primary suppliers of metoprolol succinate include Novartis (branded Toprol-XL), Sandoz, Teva, Viatris (Mylan), and Sun Pharmaceuticals. The API manufacturing base is concentrated mainly in China and India, with finished product production dispersed globally. Supply chain stability hinges on API manufacturing facilities' compliance and geopolitical factors.
Key Takeaways
- Multiple suppliers produce generic and branded metoprolol succinate, with Sandoz and Teva leading generic production.
- API manufacturing is mainly centralized in China and India; finished product production is global.
- Market share remains fragmented, but large firms dominate volume.
- Regulatory compliance ensures supply chain reliability.
FAQs
-
Who are the top manufacturers of metoprolol succinate?
Novartis (brand: Toprol-XL), Sandoz, Teva, Viatris, and Sun Pharmaceuticals.
-
Where is the active pharmaceutical ingredient (API) for metoprolol succinate produced?
Primarily in China (Zhejiang Huahai) and India (Synthesis Pharmaceutica).
-
What is the capacity of global metoprolol succinate production?
API capacity exceeds 10,000 tons annually; finished dosage capacity over 500 million tablets per year.
-
What are supply risks associated with metoprolol succinate?
Disruptions in API supply due to geopolitical issues or manufacturing outages could affect global availability.
-
How do regulatory agencies impact supplier credibility?
Approvals and GMP compliance from FDA, EMA, and other agencies are essential for market access and supply stability.
References
[1] IQVIA. (2022). Global Prescription Drug Market Analysis. IQVIA Reports.
